ACAD Share Price

Open 32.21 Change Price %
High 32.30 1 Day -0.88 -2.72
Low 31.31 1 Week -0.34 -1.07
Close 31.43 1 Month 2.87 10.05
Volume 1226497 1 Year 7.64 32.11
52 Week High 42.29
52 Week Low 16.64
ACAD Important Levels
Resistance 2 32.35
Resistance 1 31.97
Pivot 31.68
Support 1 30.89
Support 2 30.51
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DRYS 1.01 -36.48%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
MU 21.71 -2.73%
More..
NASDAQ USA Top Gainers Stocks
BGMD 0.07 133.33%
LOCM 0.09 50.00%
NFEC 1.28 40.66%
BASI 0.90 28.57%
URRE 2.68 27.62%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
GRVY 20.96 23.15%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

ACAD Technical Analysis 4
As on 19th Jan 2017 ACAD Share Price closed @ 31.43 and we RECOMMEND Buy for LONG-TERM with Stoploss of 29.83 & Strong Buy for SHORT-TERM with Stoploss of 27.92 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACAD Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ACAD Other Details
Segment EQ
Market Capital 128332624.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.acadia-pharm.com
ACAD Address
ACAD
11085 Torreyana Road
Suite 100
San Diego, CA 92121
United States
Phone: 858-558-2871
Fax: 858-558-2872
Interactive Technical Analysis Chart ACADIA Pharmaceuticals Inc. ( ACAD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ACADIA Pharmaceuticals Inc.
ACAD Business Profile
ACADIA Pharmaceuticals Inc., incorporated in 1993, is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831. The Company used its drug discovery platform to discover additional product candidates. These include two preclinical programs that provide the potential for disease-modifying therapies for treating Parkinson’s disease and other neurological disorders. Corporate Headquarters of the Company is at 11085 Torreyana Road, Ste. 100, San Diego, CA 92121-1104.